Development of Free Testosterone Chemiluminescence Detection Kit and Its Clinical Application
Journal of Analytical Methods in Chemistry · 2026-01 · 2026 (1)
DOI: 10.1155/jamc/5165899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Analytical Methods in Chemistry, online erschienen am 28.04.2026. Verfasst von Shuang Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China, jiangnan.edu.cn. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Free testosterone (FT), the bioactive form comprising 1%–2% of total testosterone, directly enters cells. Unlike total testosterone, FT levels are less affected by sex hormone–binding globulin and better reflect biological activity. Accurate serum FT measurement is crucial for diagnosing conditions like male hypogonadism, PCOS, metabolic syndrome, osteoporosis, and Alzheimer’s. However, existing methods suffer from inadequate sensitivity, complexity, and high cost, necessitating improved detection technologies. We developed and evaluated a chemiluminescence assay kit for FT.
Methods
FT was quantified using a competitive immunoassay where sample FT competes with acridinium ester‐labeled testosterone derivatives for binding to biotinylated antitestosterone antibodies on magnetic beads. Key parameters (magnetic bead concentration, biotinylation, labeling, and antibody/derivative concentrations) were optimized. Kit performance was rigorously assessed for linearity, limit of blank (LoB), accuracy, precision, stability, specificity, and clinical relevance. FT levels were measured in 1615 male and 2035 female patient samples to analyze clinical significance.
Results
The assay demonstrated excellent linearity ( r > 0.99), low LoB (0.021 pg/mL), high accuracy (deviation < 5%), precision (CV < 5%), and 12‐month stability. Specificity testing showed no cross‐reactivity. Method comparison with 392 clinical samples yielded a strong correlation ( r = 0.9941). Analysis of patient samples revealed significant FT level differences among males with various diagnoses: lower levels in prostate cancer patients and higher levels in conditions like hair loss.
Conclusion
The developed chemiluminescence FT assay kit exhibits superior performance, low cost, and high automation, fully meeting clinical requirements. FT measurement provides a valuable reference for diagnosing and assessing specific diseases, aiding improved clinical management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China, jiangnan.edu.cn.
- Wuxi Medical College, Jiangnan University, Wuxi, Jiangsu, China, jiangnan.edu.cn.
- Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China, jiangnan.edu.cn.
ORCID-Profile: Shuang Han, Zhixian Lu, Xuan Huang
Zitieren
APA
Han, S., Liu, M., Zhao, S., Yan, W., Lu, Z., & Huang, X. (2026). Development of Free Testosterone Chemiluminescence Detection Kit and Its Clinical Application. Journal of Analytical Methods in Chemistry, 2026(1). https://doi.org/10.1155/jamc/5165899
Vancouver
Han S, Liu M, Zhao S, Yan W, Lu Z, Huang X. Development of Free Testosterone Chemiluminescence Detection Kit and Its Clinical Application. Journal of Analytical Methods in Chemistry. 2026;2026(1). doi:10.1155/jamc/5165899
BibTeX
@article{Han2026,
author = {Han, Shuang and Liu, Min and Zhao, Simin and Yan, Wenjun and Lu, Zhixian and Huang, Xuan},
title = {Development of Free Testosterone Chemiluminescence Detection Kit and Its Clinical Application},
journal = {Journal of Analytical Methods in Chemistry},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jamc/5165899}
}
EUVIMED